Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 1
2007 1
2008 2
2011 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Adherence to enfuvirtide and its impact on treatment efficacy.
Rockstroh J, Dejesus E, Donatacci L, Wat C, Bertasso A, Labriola-Tompkins E, Shikhman A, Atkins B, Guimaraes D, Wilkinson M, Thommes J, Rowell L, Demasi R, Salgo M. Rockstroh J, et al. Among authors: donatacci l. AIDS Res Hum Retroviruses. 2008 Feb;24(2):141-8. doi: 10.1089/aid.2006.0231. AIDS Res Hum Retroviruses. 2008. PMID: 18240965 Clinical Trial.
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, Walmsley S, Cohen C, Kuritzkes DR, Eron JJ Jr, Chung J, DeMasi R, Donatacci L, Drobnes C, Delehanty J, Salgo M; TORO 1 Study Group. Lalezari JP, et al. Among authors: donatacci l. N Engl J Med. 2003 May 29;348(22):2175-85. doi: 10.1056/NEJMoa035026. Epub 2003 Mar 13. N Engl J Med. 2003. PMID: 12637625 Free article. Clinical Trial.
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials.
Nelson M, Arastéh K, Clotet B, Cooper DA, Henry K, Katlama C, Lalezari JP, Lazzarin A, Montaner JS, O'Hearn M, Piliero PJ, Reynes J, Trottier B, Walmsley SL, Cohen C, Eron JJ Jr, Kuritzkes DR, Lange J, Stellbrink HJ, Delfraissy JF, Buss NE, Donatacci L, Wat C, Smiley L, Wilkinson M, Valentine A, Guimaraes D, Demasi R, Chung J, Salgo MP. Nelson M, et al. Among authors: donatacci l. J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):404-12. doi: 10.1097/01.qai.0000185314.56556.c3. J Acquir Immune Defic Syndr. 2005. PMID: 16280694 Clinical Trial.
TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals.
Reynes J, Arastéh K, Clotet B, Cohen C, Cooper DA, Delfraissy JF, Eron JJ, Henry K, Katlama C, Kuritzkes DR, Lalezari JP, Lange J, Lazzarin A, Montaner JS, Nelson M, O' Hearn M, Stellbrink HJ, Trottier B, Walmsley SL, Buss NE, Demasi R, Chung J, Donatacci L, Guimaraes D, Rowell L, Valentine A, Wilkinson M, Salgo MP. Reynes J, et al. Among authors: donatacci l. AIDS Patient Care STDS. 2007 Aug;21(8):533-43. doi: 10.1089/apc.2006.0174. AIDS Patient Care STDS. 2007. PMID: 17711378 Clinical Trial.